Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

ImClone Systems initiates enrollment in phase II C225/CPT-11 trial

Oct. 13, 1999

SU-5416: promising phase I findings presented at ICAAC; update on clinical status

Oct. 13, 1999

Nonpeptide modulators of GnRH release patented by Alanex

Oct. 13, 1999

New British Biotech esters inhibit tumor cell proliferation

Oct. 12, 1999

Gemin X discovers novel Bcl-2 inhibitor as anticancer agent

Oct. 12, 1999

EM-800 unexpectedly found to resemble raloxifene more closely than fulvestrant

Oct. 12, 1999

Venlafaxine as a nonhormonal treatment for hot flashes associated with androgen deprivation

Oct. 12, 1999

AEterna accelerates clinical development of AE-941

Oct. 8, 1999

NCI supports further study of anticancer drugs at Lorus

Oct. 6, 1999

CRC investigators present proof that the angiogenesis theory works in patients

Oct. 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...